Noble Financial Upgrades Zomedica (NYSEAMERICAN:ZOM) to "Strong-Buy"

Zomedica (NYSEAMERICAN:ZOM - Get Free Report) was upgraded by Noble Financial to a "strong-buy" rating in a research note issued on Monday,Zacks.com reports.

Zomedica Stock Up 17.3 %

Shares of ZOM stock traded up $0.02 during trading on Monday, hitting $0.14. The company's stock had a trading volume of 25,571,575 shares, compared to its average volume of 4,687,302. The firm has a market cap of $140.72 million, a PE ratio of -2.05 and a beta of 1.06. Zomedica has a 52 week low of $0.12 and a 52 week high of $0.23.

Institutional Investors Weigh In On Zomedica

An institutional investor recently raised its position in Zomedica stock. Virtu Financial LLC increased its holdings in Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) by 1,585.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 168,773 shares of the company's stock after buying an additional 158,757 shares during the period. Virtu Financial LLC's holdings in Zomedica were worth $25,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.95% of the company's stock.

Zomedica Company Profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.